



Acute onset of idiopathic very severe aplasticanemia (vSAA, neutrophils <0.23109/L ) in ayoung patient may require urgent transplan-
tation.1 Invasive aspergillosis is a life-threatening
complication in aplastic patients, because anti-
mycotic treatment is ineffective in the absence of
neutrophils2 and the presence of the infection is a
serious obstacle to transplant procedures. We were
able to perform a successful transplant in a young
man suffering from vSAA who presented with dis-
seminated pulmonary aspergillosis by treating the
mycotic infection with amphotericin B and transfu-
sions of granulocytes that had been harvested from
G-CSF-stimulated donors.
Case Report
R. V., a 19-year-old male, was in excellent clinical
condition in February 1995 when he was called up
for military service.
About two weeks later, without any apparent
cause, he became pale and asthenic and developed
high grade fever. Admitted to a local hospital, he
was found to be suffering from severe pancytope-
nia and bilateral pneumonia and he was trans-
ferred to our unit on February 24, 1995. A diagno-
sis of idiopathic vSAA (neutrophils < 0.23109/L,
platelets 33109/L, desert bone marrow) was made,
with documentation by CT scan and microbiology
of rhinosinusitis and bilateral pneumonia due to
Aspergillus fumigatus (Figure 1a).
Since the patient had an HLA-identical brother,
an urgent bone marrow transplant was planned. In
the meantime we treated his life-threatening inva-
sive mycosis by combining amphotericin B (Fungi-
zone, Squibb, 1.5 mg/kg/d from March 7, total
dose 3.5 g) with granulocyte transfusions given
every other day before and after transplant. Condi-
tioning (cyclophosphamide 50 mg/kg/d for 4 days)
was started on day 20 from the onset of symptoms
(day 14 from diagnosis). Bone marrow cells given:
3.633108/kg. GvHD prophylaxis consisted of
cyclosporin A 3 mg/kg/d from days –1 to +20 iv,
then 10 mg/kg/d orally for one year. The patient
also received GM-CSF (Molgramostim, Schering-
Plough, 300 mg/d from days +1 to +30) and G-
CSF (Filgrastim, Amgen, 300 mg/d from days +9 to
+30), itraconazole (400 mg/d from day +27), acy-
clovir (from days –7 to +30), polyspecific (30 g
twice weekly) and anti-CMV (100 mL, twice week-
ly) IgG. Time to neutrophil (> 0.53109/L) and
Granulocyte transfusions from G-CSF stimulated
donors were added to standard anti-infective
treatment in preparation for and during allogeneic
bone marrow transplantation in a young man
affected by very severe acute aplastic anemia and
invasive aspergillosis. Nine concentrates with a
mean neutrophil content of 18.73109/L (2.63
108/kg patient b.w.) were transfused before and
after marrow infusion. An impressive clinical
improvement was noticed after each granulocyte
transfusion, although this was not always paral-
leled by a neutrophil increase in the peripheral
blood. Engraftment (N >0.53109/L and Plt
>253109/L) was verified at +16 and +40 days,
respectively. The patient is currently in complete
hematological and microbiological remission 14
months after transplantation. Granulocyte aphere-
sis from G-CSF stimulated donors provides a high
number of activated neutrophils. At the dose given
(300 µg/day) donor tolerance to G-CSF was excel-
lent. This new approach is indicated when life-
threatening infections develop in patients exposed
to prolonged severe neutropenia. 
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platelet (>253109/L) recovery was +16 and +40
days, respectively. Microbiology became negative
within two weeks. At day +46 a repeat ampho-
tericin B course (100 mg every other day, total 3 g)
was required because of a recurrence of fever and
the presence of aspergillus in the sputum. No signs
of acute or chronic graft versus host disease
appeared during the post-transplant period. In
October 1996, 19 months after transplantation,
the patient is in complete hematological and
microbiological remission (Figure 1b).
Granulocyte apheresis from G-CSF-stimulated donors
Nine granulocyte concentrates obtained from
three donors were infused over two weeks. Aphere-
ses were performed with relatives of the patient
(including the bone marrow donor) who shared
the same blood group; the patient and the donors
were all positive for anti-CMV IgG. In order to
avoid presensitization against donor antigens, the
bone marrow donor was utilized as a granulocyte
donor only after transplantation. After giving
informed consent, each donor received 300 µg of r-
metHuG-CSF (Filgrastim, Amgen) once a day for 5
days. Their circulating neutrophils immediately
peaked between 30 and 403109/L; moderate bone
pain was the only complaint. Apheresis procedures
were performed every other day and were well toler-
ated. Mean bag content was 18.73109 neutrophils.
Each bag was irradiated before infusion. 
Comment
Aspergillosis is usually a late complication of AA,
often triggered by immunosuppressive treatments;
in our patient invasive aspergillosis was diagnosed
simultaneously with vSAA before any treatment was
given. An aplastic patient with invasive aspergillosis
is the worst possible candidate for a bone marrow
trasplant. A recent review3 reports that only 10% of
aplastic patients with invasive aspergillosis respond
to standard anti-fungal treatment. Transfusion of
granulocytes to prevent or treat infection in neu-
tropenic patients was studied in the 70’s.4 Reduc-
tion of bacterial infections and mortality were
described, but harvest yield was low and concern
was raised about the possibility of pulmonary dam-
age.5 Nowadays, the availability of colony-stimulat-
ing factors has increased the neutrophil yield up to
six times, without significant side-effects in the
donor;6 neutrophil function in the harvest is fully
retained or even increased.7 This has triggered new
interest in granulocyte transfusion.8
The favorable outcome in our patient suggests
that granulocyte transfusion should be included in
the treatment strategy for such patients. Lung
sequestration is a well-known phenomenon after
granulocyte infusion,9 which in this case may have
favored the resolution of the pneumonia. Also, it is
possible that neutrophil activation by growth fac-
tors played some role in the antimycotic defense.10
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Figure 1.  A: an excavated lesion caused by Aspergillus fumigatus
in the left lung, before transplant.  B: Complete recovery five
months later. 
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